Ticari basın bülteni

GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure

06 Jul 2021

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Contact

Dr. Michael Golek

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

GEA Hakkında

GEA, 2019 yılında 4,9 milyar EUR konsolide geliri ile gıda işleme endüstrisi ve diğer birçok endüstri için en büyük tedarikçilerden birisidir.

Haberleri GEA’dan alın

GEA haber bültenine abone olarak GEA yeniliklerinden ve hikayelerinden haberdar olun.

Bizimle iletişime geçin

Size yardımcı olmak için buradayız! Sadece bir kaç detay ile sorunuza yanıt verebileceğiz.